Physician profile
Danielle Butler
NPI 1730482951
$2,334.91
in general payments reported to CMS, 2019-2025
23 companies · $50.26 in 2025
The $50.26 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.11 · 2022: $445 · 2023: $1,182 · 2024: $635 · 2025: $50.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $473.21 | 2023-2024 | Breztri, Fasenra, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.31 | 2022-2023 | |
| Amgen INC. | $142.66 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $139.87 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $138.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $91.58 | 2022-2023 | Rexulti, Nuedexta |
| Corcept Therapeutics | $86.09 | 2023 | Korlym |
| Halozyme INC | $62.18 | 2023 | |
| Ucb, INC. | $53.42 | 2024 | Cimzia |
| Axsome Therapeutics, INC. | $46.15 | 2024 | Auvelity |
| Lilly USA, LLC | $31.69 | 2023-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $24.31 | 2024 | |
| Inspire Medical Systems, INC. | $22.07 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $21.76 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $21.43 | 2024 | Yupelri |
| Grifols USA, LLC | $17.72 | 2024 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $16.90 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.95 | 2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.36 | 2025 | Trulance, Xifaxan |
| Neurocrine Biosciences, INC. | $14.88 | 2022 | |
| Antares Pharma, INC. | $13.07 | 2023 | Xyosted, Tlando, Nocdurna |
| Biohaven Pharmaceutical Holding Company LTD. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.